Moleculin Biotech
MBRX
20 hedge funds and large institutions have $1.33M invested in Moleculin Biotech in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 5 closing their positions.
0.01% less ownership
Funds ownership: 0.03% → 0.02% (-0.01%)
9% less funds holding
Funds holding: 22 → 20 (-2)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
54% less capital invested
Capital invested by funds: $2.91M → $1.33M (-$1.58M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
+$37.5K |
| 2 |
Millennium Management
New York
|
+$23.7K |
| 3 |
Renaissance Technologies
New York
|
+$23.2K |
| 4 |
PJSIMP
P.J. Schmidt Investment Management (PJS)
Cedarburg,
Wisconsin
|
+$20.3K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.32K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$498K |
| 2 |
BlackRock
New York
|
-$44.1K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$30.6K |
| 4 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
-$28.5K |
| 5 |
VF
Virtu Financial
New York
|
-$16K |
MBRX Hedge Fund Activity: Q2 2023 in Review
20 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q2 2023, worth a combined $1.33M — down 54% from $2.91M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of MBRX and 3 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was Squarepoint, adding an estimated $37.5K. The largest seller was Sio Capital Management, cutting an estimated $498K.
- 20 institutional investors held Moleculin Biotech (MBRX) as of Q2 2023, down from 22 in Q1 2023.
- Funds reported $1.33M of Moleculin Biotech stock for Q2 2023, down 54% quarter-over-quarter.
- 3 funds opened new Moleculin Biotech positions in Q2 2023 and 5 closed out, a net change of -2 holders.
- The largest Moleculin Biotech buyer in Q2 2023 was Squarepoint, an estimated $37.5K added.
- The largest Moleculin Biotech seller in Q2 2023 was Sio Capital Management, an estimated $498K sold.
Based on aggregated 13F filings for Q2 2023.